ArticleTargeted oncology2022

Correction to: Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors.

Amita Patnaik et al.PubMed ↗Publisher ↗

No numbers read from the abstract.